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Background: Pyrogen detection is of utmost importance in pharmaceutical industry, laboratories and health care
institutions. As an alternative to the animal-consuming rabbit pyrogen test or Limulus amoebocyte lysate test, the
monocyte activation test was introduced as a gold standard method in the European Pharmacopoeia. However, the
monocyte activation test has not gained wide acceptance in practice.
Methods: We stimulated bovine whole blood with different endotoxin preparations (lipopolysaccharide E.coli 0127:
B8 and 0113:H10), as well as the non-endotoxin pyrogens peptidoglycan and lipoteichoic acid. Prostaglandin E2 (PGE2)
served as read out.
Results: Employing PGE2 as read out enabled detection limits of 0.04 EU/ml for lipopolysaccharide 0127:B8, 0.25 EU/ml
for lipopolysaccharide 0113:H10 and 10 μg/ml of lipoteichoic acid as well as peptidoglycan. To evaluate the bWBA test
system as a possible alternative to the MAT we performed a peer-to-peer comparison of the two methods and confirmed
similar sensitivities.
Conclusions: In conclusion, the bovine whole blood assay (bWBA) reproducibly enabled sensitive detection of endotoxin
and non-endotoxin pyrogens and may thus become a viable alternative for pyrogen testing.
Keywords: Endotoxin, Bovine whole blood, Prostaglandin E2, Pyrogen, Monocyte activation test, Lipopolysaccharide,
Lipoteichoic acidBackground
The detection of pyrogenic contamination is an essential
part of drug safety testing in the pharmaceutical industry,
reference laboratories as well as health care institutions.
To guarantee patient safety, critical threshold levels of
pyrogenic contamination have been determined and must
not be exceeded. Therefore the European Pharmacopoeia
(EP) promotes the monocyte activation test (MAT) as most
suitable test for pyrogen testing [1]. Former methods, the
rabbit pyrogen test (RPT) [2] and the Limulus amoebocyte
lysate (LAL) test [3] are limited by inherent disadvantages
since the RPT has a comparably low sensitivity for pyro-
gens [4] and the LAL is unable to detect non-endotoxin
pyrogens [5]. Moreover, both are animal-consuming tests* Correspondence: Manfred.Kietzmann@tiho-hannover.de
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article, unless otherwise stated.which, according to the 3 R concept – replacement, reduc-
tion, refinement –, should be avoided [6-8].
Nevertheless, product safety has to remain the first
priority of medical product legislation, while economic
considerations are also important to the industry and
suitable methods need to offer a reasonable cost-benefit
ratio. The MAT utilizes human blood [9,10] and is char-
acterized by a high sensitivity for detecting endotoxin and
non-endotoxin pyrogens. However, apparently it did not
satisfy the needs of the pharmaceutical industry because it
has not been widely used since its introduction in 2010.
This might be partly due to the fact that accessing fresh
human whole blood or producing large amounts of
cryoblood of uniform quality for use in the MAT is cer-
tainly a logistic challenge. According to the European
Pharmacopoeia, blood donors must confirm that they
have been free of signs of infection and have not taken
anti-inflammatory medications for one week beforentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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routinely tested for sterility and HIV, HAV, HCV and
HBV [11]. However, there remain several potentially
influencing factors that cannot be standardized in a
human-based test system since lifestyle and genetic
background certainly differ significantly between donors.
In principal, if blood from a large animal species and a
designated breed would be used for pyrogen detection
most of these limitations could be overcome, because
the animals can be housed under standardized specific
pathogen-free conditions. Several aspects favor the use
of bovine blood, for instance the fact that the Toll-like
receptor equipment of bovine leukocytes is comparable
to humans [12] as well as reports suggesting the suitability
of bovine blood for the detection of lipopolysaccharides
(LPS) [13].
In a previous study we reported that bovine whole blood
can be used for a sensitive detection of LPS 0111:B4 from
E.coli by using Prostaglandin E2 as readout [14]. In the
present study we investigated whether the system we
established was also capable of detecting other endotoxins
and gram-positive cell wall components. Additionally, we
compared our method with the commercially available
PyroDetect System (MAT) in a peer-to-peer setup.
Methods
Used stimulants
Endotoxin derived from Escherichia coli 0127:B8 (L3129,
Sigma-Aldrich, Steinheim, Germany; stock ≥ 500000
EU/mg), WHO standard endotoxin from Escherichia coli
0113:H10:K (10 000 IU per vial, Merck, Darmstadt,
Germany), peptidoglycan from Bacillus subtilis (low
endotoxin, ≤ 1 EU/mg, InvivoGen, Toulouse, France) and
lipoteichoic acid from Staphylococcus aureus (low endo-
toxin, ≤ 1 EU/mg, InvivoGen) were used as stimulants.
Solutions were prepared with LAL-water or pyrogen-free
saline. Aliqouts were stored at −20°C, except for the
WHO Endotoxin, which was stored at −80°C. Immediately
prior to use the aliquots were thawed, sonicated and
diluted with pyrogen-free saline into different concentra-
tions. Concentrations used for LPS 0127:B8 were 0.039,
0.078, 0.156, 0.313, 0.625 and 1.25 EU/ml, for LPS 0113:
H10 0.063, 0.125, 0.25, 0.5, 1 and 2 EU/ml. Peptidoglycan
and lipoteichoic acid were diluted to 1, 10, 50, 100 and
1000 μg/ml.
Blood collection and ethical statement
Blood was obtained via venipuncture from healthy cattle
(mainly Holsteins except two crossbreds and one red
Holstein) into 7.5 ml heparinized tubes (Li-Heparin,
19 IU/ml, SARSTEDT Monovette, Nümbrecht, Germany).
The animals were owned by and stabled in the Clinic for
Cattle of the University of Veterinary Medicine Hannover,
Foundation. All blood donors were female, non-lactatingcows and were fed with hay ad libitum. The age ranged
from 2.5 to 13 years.
This study received ethical approval by the Lower Saxony
State Office for Consumer Protection and Food Safety
(LAVES), Oldenburg (Az. 33.9-42502-05-13A361). All pro-
cedures involving animals were carried out in accordance
with German legislation on animal welfare.
In vitro assay using bovine peripheral blood
225 μl lithium heparin blood from different donors were
pipetted into 96-well cell culture plates (SARSTEDT,
Nümbrecht, Germany) and stimulated for 24 hours with
25 μl pyrogen solution or vehicle. After incubation at
37°C and 5% CO2, the 96-well plates were centrifuged at
2272 × g for 10 minutes, the supernatants were collected
and frozen at −80°C until analysis. PGE2 concentration
was determined using the Cayman Prostaglandin E2
Express EIA Kit (Cayman Chemical Company, Ann Arbor,
MI, USA) following the manufacturer’s instructions.
Comparison with the PyroDetect system
The PyroDetect System (Merck, Darmstadt, Germany)
was used according to the manufacturer’s instructions as
a quantitative test with the exception that samples were
not tested at different dilutions. The quantitative test is
described by the producers as method A. By using method
A, a quantitative comparison of the samples with the
standard endotoxin is possible. In summary, the stimulat-
ing agents were pipetted as 20 μl portions into the 96-well
plate (included in the kit) under a horizontal flow bench.
Apart from the spike and blank wells – the former was
filled with stimulant and spiked RPMI medium, the latter
with a total of 40 μl RPMI – 20 μl RPMI were added to
each well. The two cryo blood vials (included in the kit)
were thawed in a water bath for 1 minute and diluted im-
mediately with 8 ml RPMI 1640 cell culture medium each
(included in the kit). Afterwards the cryopreserved blood
mixture was pipetted into the plate at a volume of 200 μl
per well. After incubation for 16 hours at 37°C with 5%
CO2 the mixture in the wells was resuspended five times
and transferred to the ELISA plate (included in the kit).
The IL-1β ELISA was performed following the manufac-
turer’s instructions. To compare this test system with the
bovine whole blood assay the same stimulants (diluted in
RPMI) were tested simultaneously using the blood of 6
animals (separately) following the method described before.
Statistical analysis
Statistical analysis was carried out using the software
SAS 9.3 (SAS, Cary, NC, USA). Data were checked
for normal distribution by visual inspection and the
Kolmogorov-Smirnov test. Some data sets showed a
left-skewed distribution and failed the normality test.
Therefore a permutation test (10000 permutations) was
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(equivalent to exact Friedmann Test) and P values smaller
0.05 were considered significant. Calculations were done
with the SAS macro RIBDPERM.MAC (provided by Erich
Schumacher, Institut für Angewandte Mathematik und
Statistik, Universität Hohenheim). Data are represented as
box-plot with median and min to max whiskers.Figure 2 Stimulation with WHO standard endotoxin.
Prostaglandin E2 concentration after LPS stimulation of fresh (stored <
2 h) bovine whole blood. Box-plot with median and min to max
whiskers of n = 5, permutation test, *p≤ 0.05, **p≤ 0.01 compared to
unstimulated blood. Result is representative of three independent
experiments1.Results
Pyrogen stimulation
LPS from E.coli 0127:B8 was used as a stimulating agent
and we found a dose-dependent increase of PGE2 starting
at a dose of 0.08 EU/ml and reaching a plateau at 0.16
EU/ml (Figure 1). Using the WHO standard endotoxin
(LPS E.coli 0113:H10) we discovered a dose-dependent
increase of PGE2 release starting at 0.25 EU/ml (Figure 2).
Peptidoglycan (PGN) from Bacillus subtilis induced a
dose-dependent increase of PGE2 in concentrations of
more than 10 μg/ml (Figure 3). Likewise, lipoteichoic acid
(LTA) from Staphylococcus aureus provoked a significant
increase of PGE2 at concentrations of 10 μg/ml and above
(1 μg/ml provoked an increase as well, but fell just short
of the level of significance, p = 0.056). The maximum
PGE2 production was seen at 50 μg/ml, but although
eicosanoid release elicited by higher LTA concentrations
declined, it remained significantly higher compared to
unstimulated blood (Figure 4).Bovine whole blood assay compared to PyroDetect
system
After 16 hours of stimulation – analogously to the
manufacturer’s lab procedure – the PyroDetect System
ELISA detected the presence of 0.25 EU/ml standardFigure 1 Stimulation with LPS from E.coli 0127:B8. Prostaglandin
E2 concentration after LPS stimulation of fresh (stored < 2 h) bovine
whole blood. Box-plot with median and min to max whiskers of n = 9,
permutation test, *p≤ 0.05, **p≤ 0.01 compared to unstimulated blood.
Result is representative of three independent experiments1.endotoxin (Figure 5), whereas 0.0625 EU/ml and 0.125
EU/ml did not induce measurable cytokine production.
Importantly, the PyroDetect System also detected the
presence of all other pyrogens at all concentrations used.
Unfortunately, the color reaction of the ELISA was so
intense that we were unable to quantify it thus preclud-
ing the specification of EU equivalents.
The simultaneous stimulation of bovine blood from 6
animals with the same pyrogens resulted in detection
limits comparable to those obtained from the previous
experiments. Results of one animal were excluded from
analysis because of preexisting PGE2 release from theFigure 3 Stimulation with peptidoglycan from Bacillus subtilis.
Prostaglandin E2 concentration after PGN stimulation of fresh (stored <
2 h) bovine whole blood. Box-plot with median and min to max
whiskers of n = 5, permutation test, **p ≤ 0.01 compared to
unstimulated blood. Result is representative of three independent
experiments1.
Figure 4 Stimulation with lipoteichoic acid from
Staphylococcus aureus. Prostaglandin E2 concentration after LTA
stimulation of fresh (stored < 2 h) bovine whole blood. Box-plot with
median and min to max whiskers of n = 5, permutation test, **p≤ 0.01
compared to unstimulated blood. Result is representative of three
independent experiments1.
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the two test methods are given in Table 1.
Discussion
We have previously shown that LPS 0111:B4 from E.coli
can be reliably detected using a bovine whole blood
assay and PGE2 as readout [14]. Hartung and Wendel
[15] reported the suitability of a test method utilizing
human whole blood for the detection of endotoxin as
well as non-endotoxin pyrogens. The quite similar toll-
like receptor (TLR) equipment of human and bovine
leukocytes [12] gave reason to expect the same would beFigure 5 PyroDetect System standard curve. PyroDetect System
WHO standard endotoxin calibration curve, optical density in relation
to LPS concentration. Mean with SEM of pooled cryoconserved human
blood in 4 measurements.possible using our test system. Thus, we decided to in-
vestigate whether the bovine whole blood assay was cap-
able of detecting a broad range of pyrogens with the
required sensitivity.Detection of LPS
The bWBA was capable of detecting the presence of two
different kinds of endotoxins. Remarkably, the detection
of LPS 0127:B8 was 3 – 6 fold more sensitive than the
detection of LPS 0113:H10 (0.04 – 0.08 EU/ml vs. 0.25 –
0.5 EU/ml) which was confirmed using the PyroDetect
System. Similar findings were reported by others who
showed an up to 1000-fold difference in potency of dif-
ferent endotoxins [16,17]. However, the observed detec-
tion limits of both test systems for the WHO standard
endotoxin (LPS E.coli 0113:H10) still complied with the
specifications of the MAT and the required sensitivity of
pyrogen testing of 0.5 EU/ml [1].
Detection of PGN
The bWBA was capable of detecting 10 – 50 μg/ml PGN.
It is still a matter of controversy how the stimulatory po-
tency of PGN is conveyed. Although it has long been
thought to be an agonist of the TLR2, PGN is probably
sensed by the nucleotide-binding oligomerization domain-
containing proteins (NOD) 1 and 2 [18]. Moreover, it has
been reported that commercial PGN preparations are
often contaminated with endotoxin [19] and highly puri-
fied PGN was unable to stimulate cytokine release in a hu-
man whole blood test system [20,21]. This issue was also
discussed in a meta-analysis of Rockel and Hartung [22]
and to date there is no evidence that highly purified PGN
is an immune stimulant. In order to prevent the effects of
a potential endotoxin contamination we used a PGN pre-
paration from Invivogen. This manufacturer guarantees an
endotoxin content of less than 1 EU per milligram. Re-
garding that in our study detectable LPS concentrations
were in the pg/ml range, whereas non-endotoxin pyrogens
could be detected in the μg/ml range a falsification of the
results due to LPS contamination should be unlikely
although it cannot be completely excluded.
Detection of LTA
The bWBA was capable of detecting 10 μg/ml LTA.
Interestingly, we observed a decrease of PGE2 release at
the highest concentrations of LTA, a finding which has
not been reported in the literature so far. A possible ex-
planation could be a complex formation of LTA at high
concentrations [23], a phenomenon that seems to occur
because of the intermolecular interactions of LTA mole-
cules. Another explanation could be an enhanced bind-
ing by the bovine scavenger receptor type 1 [24], which
has the ability to interact with or bind, for example,
Table 1 Detection limits of the different stimulants
Detection limits
Experiment 1 Experiment 2 Experiment 3 PyroDetect System
n = 6 – 9 n = 6 n = 5 Poolblood
LPS E.coli
0.08 EU/ml 0.04 EU/ml 0.08 EU/ml 0.04 EU/ml ‡
0127:B8
LPS E.coli
not tested 0.5 EU/ml 0.25 EU/ml 0.25 EU/ml
0113:H10
Peptidoglycan
10 μg/ml 50 μg/ml 10 μg/ml 1 μg/ml ‡
Bac. subtilis
Lipoteichoic acid
10 μg/ml 10 μg/ml 10 μg/ml 1 μg/ml ‡
Staph. aureus
Different animals were used, permutation test, compared to unstimulated blood. Experiment 3 was the comparison with the PyroDetect System. ‡ = lowest
concentration tested.
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seem to apply to PGN. Yet, despite the decline of PGE2,
the high concentrations of LTA still remained detectable
and concentrations above 100 μg/ml are very unlikely to
occur in pyrogen-contaminated medicinal products.
A meta-analysis by Rockel and Hartung discussed LTA
as a possible reference stimulant for grampositive bacteria,
analogous to endotoxin for gramnegative bacteria [22].
Similar to PGN some commercial LTA preparation have
been reported to be contaminated by LPS [25], so again
we used a preparation from Invivogen to reduce the risk
of false positive results. Nevertheless, it is not clear
whether LTA itself is a pyrogen or not. Zähringer et al.
[18] elegantly elucidated how contaminating lipopetides
like MALP-2 likely explain the TLR2-stimulating effects of
LTA and PGN preparations. A TLR2-agonistic activity of
natural and synthetic lipopeptides has also been confirmed
by others [26].
Comparison of the MAT and bWBA
In order to compare the sensitivity of the bovine whole
blood assay with the commercially available PyroDetect
System we decided to perform a peer-to-peer comparison
with the same stimulants. The comparison of the two
methods resulted in the same detection level of WHO
standard endotoxin, 0.25 EU/ml – sufficing the postulated
allowed level of 0.5 EU/ml in pharmaceutical products
[1]. With regard to PGN, LTA and LPS 0127:B8 the
PyroDetect System appeared to be more sensitive. It
was capable of identifying the presence of 1 μg/ml PGN
or LTA (the lowest concentrations used in our experi-
ments) and other studies suggest that the MAT can detect
concentrations as low as 100 ng/ml LTA [25,27]. The hu-
man blood-based MAT has been validated for endotoxin
detection but there was no formal evaluation study with
respect to non-endotoxin pyrogen detection [22]. How-
ever, Hasiwa et al. [28] strongly suggested that the MAT is
able to detect non-endotoxin pyrogens and whether aformal validation is necessary is beyond the scope of this
discussion.
The inferior performance of the bovine assay in terms
of non-endotoxin pyrogens may indicate a shortcoming.
The difference in sensitivity of the two methods may
partly be due to the different endpoints used. As an acute
phase protein IL-1β is produced by blood cells only in re-
sponse to potentially dangerous exogenous stimuli, e.g.
pyrogens [29] resulting in a strong increase of its con-
centration. In contrast, certain endogenous levels of PGE2
are physiologically present in (bovine) blood. Therefore, in-
terindividual differences in basal plasma levels demanded a
quite distinct increase of eicosanoid production in order to
be statistically significant. Unfortunately, we were unable
to obtain a commercial kit suitable for the determination
of cytokines in bovine whole blood [14]. Future investiga-
tions will need to clarify whether the bWBA can be opti-
mized in order to increase its sensitivity, but the fact that
the level of significance was just barely missed after stimu-
lation with 1 μg/ml LTA seems promising.
Some medicinal products like vaccines may benefit
from in vitro pyrogen testing in the target species. Bac-
terial vaccines contain bacterial components by definition
and different species may display differing sensitivities to-
wards certain bacteria [30]. Thus, testing vaccines in the
target species may increase product safety. Considering
the diversity of veterinary species it will, however, be very
difficult to test every product in the target species, espe-
cially because many human medicinal products (with the
exception of vaccines) are used off-label in veterinary
medicine. With that said, pyrogen testing using quality-
controlled blood from cattle housed under standardized
conditions may be an option with favorable risk/benefit-
ratio.
Conclusions
With regard to the aim of reduction, refinement and re-
placement (3R) of animal experiments the introduction
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use of RPT and LAL [31]. However, this objective does
not seem to have been achieved because the MAT is not
widely used yet. Here we show the potential of detecting
endotoxin and non-endotoxin pyrogens using a bovine
whole blood assay. Further efforts are indispensable to
improve the method’s functionality, detection limits and
robustness as well as to verify whether it can detect fur-
ther pyrogens including lipopeptides. If the bWBA meets
these requirements it should be possible to produce
large standardized batches of bovine blood in reference
laboratories which could then offer pyrogen testing
services using the bWBA as an alternative to the RPT.
Endnote
1Notably, concentrations in the figures refer to the
stimulant solutions used. These were diluted tenfold in
the final setup (using 225 μl whole blood and 25 μl
stimulant). Results depicted in the figures are representa-
tive of repeated experiments. The detection limits from all
experiments are presented in Table 1.
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